Hypoxia-inducible factor

SHAREHOLDER ALERT: Robbins LLP Announces that Akebia Therapeutics, Inc. (AKBA) is Being Sued for Misleading Keryx Biopharmaceuticals, Inc. (KERX) Shareholders Ahead of Merger

Retrieved on: 
Monday, July 26, 2021
Legal, Professional services, Plants, Akebia, Flora of China, Lardizabalaceae, Hypoxia-inducible factor

Akebia is a biopharmaceutical company that develops and commercializes therapeutics for patients based on hypoxia-inducible factor ("HIF") technology.

Key Points: 
  • Akebia is a biopharmaceutical company that develops and commercializes therapeutics for patients based on hypoxia-inducible factor ("HIF") technology.
  • If you suffered a loss due to Akebia Therapeutics, Inc.'s misconduct, click here .
  • According to the complaint, the Registration Statement issued in connection with the December 2018 merger of Keryx with Akebia contained untrue statements of material fact.
  • If you owned shares of Keryx Biopharmaceuticals, Inc. and received shares of Akebia Therapeutics, Inc. (AKBA) in the December 2018 merger, contact us to discuss your options.

FibroGen Announces Outcome of FDA Advisory Committee Review of Roxadustat for Treatment of Anemia of Chronic Kidney Disease

Retrieved on: 
Thursday, July 15, 2021
Enzymes, Chemical compounds, Acetic acids, Organic compounds, Isoquinolines, Roxadustat, Hypoxia-inducible factor, Anemias, Myelodysplastic syndrome, HIF prolyl-hydroxylase inhibitor, Procollagen-proline dioxygenase, Chronic kidney disease

Roxadustat, an oral small molecule hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, is the first HIF-PH inhibitor accepted by the FDA for review for the treatment of anemia of CKD.

Key Points: 
  • Roxadustat, an oral small molecule hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, is the first HIF-PH inhibitor accepted by the FDA for review for the treatment of anemia of CKD.
  • Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia (CIA).
  • The Company is currently developing and commercializing roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylase activity, for anemia of chronic kidney disease (CKD).
  • Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia (CIA).

Akebia Therapeutics Announces Presentations at ERA-EDTA Virtual Congress 2021

Retrieved on: 
Thursday, June 3, 2021
Chemistry, Enzymes, Acetic acids, Physical sciences, Transcription factors, Hypoxia-inducible factor, Vadadustat, Procollagen-proline dioxygenase, European Renal Association – European Dialysis and Transplant Association, Hydroxylation, Hypoxia in fish, Ethylenediaminetetraacetic acid

For more information on ERA-EDTA Virtual Congress 2021, visit: https://www.era-edta.org/en/virtualcongress2021/ .

Key Points: 
  • For more information on ERA-EDTA Virtual Congress 2021, visit: https://www.era-edta.org/en/virtualcongress2021/ .
  • Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease.
  • For more information, please visit our website at www.akebia.com , which does not form a part of this release.
  • Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor designed to mimic the physiologic effect of altitude on oxygen availability.

FibroGen to Present at Upcoming Investor Conferences

Retrieved on: 
Thursday, May 27, 2021
Branches of biology, Biology, Cell biology, Transcription factors, Hypoxia-inducible factor, Growth factors, CTGF, Myelodysplastic syndrome, Roxadustat, Hypoxia in fish, HIF, Dysplasia

A replay will be available for approximately 30 days.

Key Points: 
  • A replay will be available for approximately 30 days.
  • FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics.
  • The Company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines for the treatment of unmet needs.
  • Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia (CIA).

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against FibroGen Inc. (FGEN)

Retrieved on: 
Friday, May 14, 2021
Enzymes, Life sciences, Biotechnology, Acetic acids, Isoquinolines, Roxadustat, Hypoxia-inducible factor, Hydroxylation, Procollagen-proline dioxygenase, Biopharmaceutical

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.\nFibroGen is a biopharmaceutical company that develops medicines for the treatment of anemia, fibrotic disease, and cancer.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.\nFibroGen is a biopharmaceutical company that develops medicines for the treatment of anemia, fibrotic disease, and cancer.
  • Its most advanced product is roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor-prolyl hydroxylase (\xe2\x80\x9cHIF-PH\xe2\x80\x9d) activity that acts by stimulating the body\xe2\x80\x99s natural pathway for red cell production.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • If you inquire by email please include your mailing address, telephone number and number of shares purchased.\nThis press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.\nGlancy Prongay & Murray LLP, Los Angeles\n'

FibroGen to Present at Upcoming Investor Conference

Retrieved on: 
Wednesday, April 28, 2021
Enzymes, Chemical compounds, Acetic acids, Branches of biology, Transcription factors, Isoquinolines, Roxadustat, Hypoxia-inducible factor, Myelodysplastic syndrome, HIF prolyl-hydroxylase inhibitor, Procollagen-proline dioxygenase, CTGF

A replay will be available for approximately 30 days.\nFibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics.

Key Points: 
  • A replay will be available for approximately 30 days.\nFibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics.
  • The Company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines for the treatment of unmet needs.
  • The Company is currently developing and commercializing roxadustat, an oral small molecule inhibitor of HIF prolyl hydroxylase activity, for anemia associated with chronic kidney disease (CKD).
  • Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia (CIA).

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against FibroGen Inc. (FGEN)

Retrieved on: 
Wednesday, April 21, 2021
Legal, Professional services, Hypoxia-inducible factor, XE-class submarine

b'Law Offices of Howard G. Smith reminds investors of the upcoming June 11, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired FibroGen Inc. (\xe2\x80\x9cFibroGen\xe2\x80\x9d or the \xe2\x80\x9cCompany\xe2\x80\x9d) (NASDAQ: FGEN ) securities between November 8, 2019 and April 6, 2021, inclusive (the \xe2\x80\x9cClass Period\xe2\x80\x9d).\nInvestors suffering losses on their FibroGen investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to [email protected] .\nFibroGen is a biopharmaceutical company that develops medicines for the treatment of anemia, fibrotic disease, and cancer.

Key Points: 
  • b'Law Offices of Howard G. Smith reminds investors of the upcoming June 11, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired FibroGen Inc. (\xe2\x80\x9cFibroGen\xe2\x80\x9d or the \xe2\x80\x9cCompany\xe2\x80\x9d) (NASDAQ: FGEN ) securities between November 8, 2019 and April 6, 2021, inclusive (the \xe2\x80\x9cClass Period\xe2\x80\x9d).\nInvestors suffering losses on their FibroGen investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to [email protected] .\nFibroGen is a biopharmaceutical company that develops medicines for the treatment of anemia, fibrotic disease, and cancer.
  • Its most advanced product is roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor-prolyl hydroxylase (\xe2\x80\x9cHIF-PH\xe2\x80\x9d) activity that acts by stimulating the body\xe2\x80\x99s natural pathway for red cell production.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to [email protected] , or visit our website at www.howardsmithlaw.com .\nThis press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210421005863/en/\n'

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against FibroGen Inc. (FGEN)

Retrieved on: 
Monday, April 19, 2021
Legal, Professional services, Enzymes, Chemistry, Acetic acids, Branches of biology, Isoquinolines, Roxadustat, Hypoxia-inducible factor, Hydroxylation, Procollagen-proline dioxygenase

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.\nFibroGen is a biopharmaceutical company that develops medicines for the treatment of anemia, fibrotic disease, and cancer.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.\nFibroGen is a biopharmaceutical company that develops medicines for the treatment of anemia, fibrotic disease, and cancer.
  • Its most advanced product is roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor-prolyl hydroxylase (\xe2\x80\x9cHIF-PH\xe2\x80\x9d) activity that acts by stimulating the body\xe2\x80\x99s natural pathway for red cell production.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • If you inquire by email please include your mailing address, telephone number and number of shares purchased.\nThis press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210419005342/en/\n'

FGEN CLASS ACTION NOTICE: Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against FibroGen Inc.

Retrieved on: 
Friday, April 16, 2021
Legal, Professional services, Hypoxia-inducible factor, Acetic acids, Roxadustat, XE-class submarine

b'Glancy Prongay & Murray LLP (\xe2\x80\x9cGPM\xe2\x80\x9d), announces that it has filed a class action lawsuit in the United States District Court for the Northern District of California captioned Gutman v. FibroGen, Inc., et al., (Case No.

Key Points: 
  • b'Glancy Prongay & Murray LLP (\xe2\x80\x9cGPM\xe2\x80\x9d), announces that it has filed a class action lawsuit in the United States District Court for the Northern District of California captioned Gutman v. FibroGen, Inc., et al., (Case No.
  • 3:21-cv-02725) on behalf of persons and entities that purchased or otherwise acquired FibroGen Inc. (\xe2\x80\x9cFibroGen\xe2\x80\x9d or the \xe2\x80\x9cCompany\xe2\x80\x9d) (NASDAQ: FGEN ) securities between November 8, 2019 and April 6, 2021, inclusive (the \xe2\x80\x9cClass Period\xe2\x80\x9d).
  • Its most advanced product is roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor-prolyl hydroxylase (\xe2\x80\x9cHIF-PH\xe2\x80\x9d) activity that acts by stimulating the body\xe2\x80\x99s natural pathway for red cell production.
  • To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class.

Otsuka and Akebia Announce Submission of New Drug Application to the FDA for Approval of Akebia’s Vadadustat

Retrieved on: 
Tuesday, March 30, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Enzymes, Chemistry, Physical sciences, Acetic acids, Pyridines, Vadadustat, Hypoxia-inducible factor, Otsuka Pharmaceutical, Hydroxylation, Procollagen-proline dioxygenase, Hypoxia in fish, HIF prolyl-hydroxylase inhibitor, Akebia’s Vadadustat, Otsuka

In 2016, Otsuka and Akebia signed a collaboration and license agreement for vadadustat in the U.S.

Key Points: 
  • In 2016, Otsuka and Akebia signed a collaboration and license agreement for vadadustat in the U.S.
  • The two companies subsequently signed a collaboration and license Agreement in 2017 for vadadustat in certain other areas.
  • Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor designed to mimic the physiologic effect of altitude on oxygen availability.
  • Otsuka established a presence in the U.S. in 1973 and today its U.S. affiliates include Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI).